# IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

> **NCT05987332** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **IDEAYA Biosciences** · enrollment: 420 (estimated)

## Conditions studied

- Metastatic Uveal Melanoma

## Interventions

- **DRUG:** IDE196
- **DRUG:** Crizotinib
- **DRUG:** Pembrolizumab
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT05987332
- **Lead sponsor:** IDEAYA Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-31
- **Primary completion:** 2027-01-15
- **Final completion:** 2028-01-15
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05987332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05987332, "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05987332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*